Is the longevity market overhyped?

What do we actually mean by the longevity market?

The longevity market is the business of extending healthspan, not the fantasy of living forever.

We should define it sharply: it is the market for measuring, delaying, and managing biological decline before it becomes disease, disability, or dependency.

That includes diagnostics, wearables, metabolic health, preventive clinics, supplements, fitness, sleep, menopause care, cognitive health, and geroscience biotech. It does not include every “anti-aging” cream or vague wellness product using longevity language.

The market has three layers.

First, consumer longevity: supplements, wearables, sleep, strength, nutrition, glucose, recovery, and health tracking.

Second, clinical longevity: biomarker panels, full-body scans, metabolic programs, hormone care, menopause care, concierge medicine, cardiovascular prevention, and cognitive screening.

Third, geroscience biotech: senescence, mitochondrial dysfunction, inflammation, immune aging, epigenetic reprogramming, autophagy, and regeneration.

Do people actually want to live longer?

Yes, demand is real. But it is not demand for immortality. It is demand to avoid the ugly part of aging: diabetes, frailty, dementia, cardiovascular disease, poor mobility, low energy, and dependency.

The spending signals are strong. For example, McKinsey found that around 70% of US and UK consumers, and 85% of Chinese consumers, had bought healthy-aging products in the prior year.

The willingness to pay is equally clear. Bain found that 51% of Asia-Pacific consumers, and 58% of Gen Z, were willing to pay more out of pocket for better healthcare outcomes, experience, and efficiency. That is the longevity opening: people pay earlier because normal healthcare intervenes too late.

But the demand is healthspan-first. Medtronic/Morning Consult found that 66% of US adults would choose a shorter healthier life over a longer unhealthy one. Roland Berger found the same pattern: 73% preferred a shorter life in very good health over a much longer life in deteriorating health.

Is longevity just a rich people thing?

Longevity is not just a rich people thing, but the current “full stack” version is absolutely built for rich people first.

The basic problem is already unequal. In the US, the richest Americans live roughly 10 to 15 years longer than the poorest Americans. That means longevity is not starting from a neutral baseline.

The same inequality shows up in the new longevity tools. Pew found that 31% of US adults in households above $75,000 regularly wore a smartwatch or fitness tracker, versus 12% below $30,000. So even the cheap-looking layer of longevity, daily health tracking, is adopted almost 3x more by higher-income households.

Then the premium stack gets expensive fast. An Oura Ring starts around $399, plus about $5.99/month for membership. Function Health sells broad biomarker testing from $365/year. Dexcom’s over-the-counter Stelo glucose sensor costs $89/month on subscription, or $99 for a one-time 30-day pack. Neko Health’s preventive body scan is cheaper than most private diagnostics at £299, but still not an impulse purchase. Full-body MRI offers can run into the $1,000–$4,000+ range depending on provider and package.

So, longevity is becoming a two-tier market.

The mass market gets steps, sleep, strength, cheaper wearables, basic bloodwork, and maybe a CGM experiment.

The affluent market gets continuous tracking, private doctors, broad biomarker panels, scans, hormone optimization, GLP-1 access, coaches, and follow-up interpretation.

Are premium longevity clinics actually useful?

The best clinics sell time compression; the worst clinics sell certainty to anxious rich people.

The valuable version compresses time: deeper bloodwork, cardiovascular checks, imaging, metabolic assessment, body composition, cognitive screening, sleep review, and physician follow-up in one coordinated plan. That solves a real problem: standard healthcare is fragmented and late.

The weak version is also obvious: sell a full-body scan, add a biological-age score, recommend supplements, and call it longevity.

Pricing exposes the category. Neko Health charges £299 for a preventive scan. Prenuvo’s whole-body MRI is around $2,499. Human Longevity offers an executive assessment with whole-genome sequencing, full-body MRI, and 120+ biomarkers. Fountain Life’s Houston memberships reportedly range from $10,500 to $85,000 per year.

The evidence does not justify blanket screening. The American College of Radiology says there is not enough evidence to recommend total-body MRI screening for asymptomatic people without risk factors or relevant family history.

That is the dividing line: targeted prevention can be useful; expensive “scan everything” medicine is often overreach.

If you want more recent data on this point, please see our latest longevity market report.

Can we actually measure aging?

We can measure signals correlated with aging, but we cannot yet measure “aging” itself with one clinical-grade number.

That is the honest answer. Aging clocks are scientifically useful, but most are not ready to guide individual medical decisions. The best ones predict risk at population level. They do not yet tell a 43-year-old exactly what to do on Monday morning.

The strongest epigenetic clocks are real research tools. Horvath’s original DNA methylation clock used 353 CpG sites and reached a 0.96 correlation with chronological age, with a 3.6-year median error in test data. GrimAge went further: it was trained around mortality-related signals, including smoking pack-years and plasma-protein proxies, and showed strong associations with lifespan, healthspan, comorbidity, type 2 diabetes, and mortality risk.

DunedinPACE is more interesting commercially because it tries to measure the pace of aging, not just biological age. It was validated across multiple datasets and associated with morbidity, disability, and mortality. That makes it closer to a “speedometer” than an “odometer.”

But the problem is validation. A 2024 Nature Medicine review was blunt: there is still no consensus on how aging biomarkers should be validated before clinical translation. That is the key point. We have predictive biomarkers, not accepted surrogate endpoints. No serious regulator treats an improved epigenetic age score as proof that a drug or protocol extends healthy life.

So we would split the field in two. Epigenetic clocks are useful for research, cohort comparison, and maybe tracking broad biological response. But for individual action today, boring biomarkers are stronger: ApoB, HbA1c, blood pressure, visceral fat, VO2 max, grip strength, bone density, sleep quality, inflammation markers, kidney function, liver function, and cognitive performance.

Can we trust biological age tests?

Biological age tests are not useless, but they are much less reliable than their marketing suggests.

The issue is not whether science exists. It does. The issue is whether a consumer can take one test, get “42.7 years old,” repeat it six months later, and know that the change means anything. Today, the answer is mostly no.

The biggest problem is noise. A Nature Aging paper found that technical variation alone could create differences of up to 9 years between replicate measurements from the same sample for several prominent epigenetic clocks.

That makes small “improvements” commercially dangerous. If a test says your biological age fell by 2 years, that may be intervention, lifestyle, lab variation, algorithmic noise, or nothing.

The second problem is disagreement between tests. Different biological-age products use different clocks, sample types, methylation sites, statistical models, and reference populations. So two companies can give the same person different “biological ages” without either being obviously fraudulent. The number is not a direct measurement like weight. It is a model output.

The third problem is actionability. A biological-age test can tell a compelling story, but it often does not tell you what to do next beyond generic advice: sleep more, exercise, lose visceral fat, improve glucose, reduce inflammation. Those are useful actions, but they do not require a $300–$500 age score to identify.

If you want more recent data on this point, please see our latest longevity market report.

Can we significantly extend life today?

We can extend life meaningfully today by reducing known risks, but we cannot yet add decades with a longevity drug.

That is the clean answer. If “life extension” means not smoking, controlling blood pressure, improving metabolic health, exercising, sleeping, and avoiding obesity, then yes, the gains can be large. Large cohort studies estimate that healthy lifestyle patterns can add roughly 5 to 10+ years of life expectancy, depending on age, baseline risk, and how many behaviors change.

But that is not the same as proving we can slow human aging itself. Today, no drug, supplement, clinic protocol, biological-age test, NAD drip, or scan package has shown in humans that it can reliably extend lifespan by 10, 20, or 30 years.

The proven longevity product today is still risk reduction, not age reversal.

Will we be able to significantly extend life in the future?

We may extend healthy life in the future, but nobody can honestly put a reliable number on it yet.

The reason to take the field seriously is animal data. Rapamycin extended median lifespan in genetically heterogeneous mice by about 23% in males and 26% in females at a higher tested dose. The National Institute on Aging’s Interventions Testing Program exists precisely because several compounds can move lifespan in mice under controlled conditions.

The reason to stay skeptical is translation. A 25% mouse lifespan gain does not mean humans get 25 more years. Humans live longer, age more slowly, have different causes of death, and cannot be tested over full lifespans in the same way. The trial endpoint problem is brutal: proving that a drug extends human life could take decades unless regulators accept validated aging biomarkers, which they have not yet done.

So the realistic future range is not “live to 150 soon.” The investable thesis is narrower: first add a few more healthy years, then maybe compound gains across cardiovascular risk, metabolic disease, immune aging, muscle loss, cognition, and cancer detection. Big jumps are possible in theory, but not forecastable with evidence today.

The future upside is real, but the number is unknowable. Anyone selling certainty on “how many years” is doing marketing, not science.

Do regulators treat aging as a disease?

No. The FDA and other major regulators do not currently treat aging itself as a disease you can approve a drug for.

That is the regulatory bottleneck behind longevity biotech. A company cannot simply run a trial saying, “our drug treats aging.”

The FDA approves drugs for specific indications, endpoints, and patient populations. Aging is still treated as a natural process, not a disease indication.

That means companies usually target age-related diseases instead: osteoarthritis, frailty, Alzheimer’s, cardiovascular disease, metabolic disease, sarcopenia, or immune decline.

The EMA is in the same logic. It has policies for medicines in older people, but that is different from recognizing aging itself as a disease. Regulators care about older patients, geriatric trial design, frailty, and age-related conditions; they do not yet approve “anti-aging drugs” as a standalone category.

WHO is more nuanced. ICD-11 includes language such as “ageing-associated decline in intrinsic capacity”, but that is not the same as saying “aging is now a disease.” It gives researchers and health systems better coding language around age-related decline, not a clean drug-approval pathway for aging reversal.

This is why trials like TAME are important. The Targeting Aging with Metformin trial was designed around whether metformin can delay multiple age-related diseases, not whether it “cures aging.”

That is the workaround: prove an intervention delays a cluster of concrete outcomes regulators already understand.

Is pet longevity moving faster than human longevity?

Yes, animal longevity is moving faster commercially because the regulatory path is easier and the trial cycle is shorter.

Dogs are the clearest case. Loyal’s LOY-001, for large dogs, received FDA “reasonable expectation of effectiveness” acceptance in 2023. LOY-002, for senior dogs, received the same FDA milestone in 2025. That does not mean the drugs are proven to extend dog lifespan yet, but it does mean the FDA’s veterinary pathway can accept a lifespan-extension claim in a way human medicine still cannot.

The science is also easier to test. A dog aging trial can produce useful lifespan and healthspan data in years, not decades. The TRIAD rapamycin trial is a randomized, double-masked, placebo-controlled, multicenter study testing whether rapamycin can extend lifespan and improve healthspan in middle-aged companion dogs.

Pets are the first real longevity market because the buyer is emotional, the endpoint is faster, and the regulator can be more flexible.

Do supplements and IV drips actually work?

Most longevity supplements and IV drips are not proven lifespan products. That is basically settled.

The strongest version of the supplement argument is NAD biology: NAD matters for metabolism, DNA repair, and cellular stress, and NAD precursors can raise NAD-related metabolites in humans.

But the clinical evidence still does not prove longer life, slower aging, or durable disease prevention in healthy people.

IV drips are weaker. Hydration and vitamins are medically useful when someone is dehydrated or deficient. For healthy people, the evidence is mostly anecdotal, while the risks are real: infection, dosing errors, contamination, and unnecessary IV access. A 2025 JAMA discussion of IV hydration spas framed the sector as popular but unproven, with uneven oversight.

The broader supplement record is not flattering either. Cochrane found no evidence supporting antioxidant supplements for mortality prevention in the general population, and beta-carotene, vitamin E, and possibly vitamin A were associated with increased mortality risk.

Supplements can correct deficiencies; they are not proven anti-aging infrastructure.

If you want more recent data on this point, please see our latest longevity market report.

Is cellular reprogramming commercially real?

Cellular reprogramming is commercially real as a venture-backed biotech bet, not as a revenue market yet.

The reason investors care is obvious: partial reprogramming tries to reverse cellular age without erasing cell identity. If it worked safely, it would be one of the biggest platforms in medicine. That is why Altos Labs launched with about $3B in funding, and why NewLimit reportedly raised $435M in 2026 around “rewinding” cellular aging in the liver.

But the clinical reality is still early. Life Biosciences has pushed partial epigenetic reprogramming toward human trials in optic neuropathies after nonhuman-primate work. That is the right first market: localized delivery, measurable tissue function, and a disease endpoint. It is not “whole-body rejuvenation.”

The main risk is safety. Reprogramming touches cell identity, proliferation, and cancer biology. The commercial question is not whether the concept is exciting. It is whether companies can control dose, tissue targeting, reversibility, immune response, and tumor risk well enough for regulators.

Cellular reprogramming is one of the highest-upside areas in longevity, but it is not a consumer longevity market.

Who is winning in longevity right now?

The current winners in longevity are the companies monetizing measurable risk: sleep, glucose, metabolic health, bloodwork, scans, and prevention.

Oura is the clearest consumer winner. By 2026, it had sold about 5.5 million rings, reached around 5 million paying subscribers, hit roughly $1 billion in 2025 revenue, and was valued around $11 billion. That is not “anti-aging biotech” but recurring health tracking around sleep, readiness, stress, heart health, women’s health, and now GLP-1 support.

Function Health is the strongest bloodwork winner. It raised $298 million in late 2025 at a $2.5 billion valuation, offers 160+ lab tests, runs through 2,000 Quest locations, and says it has completed 50 million+ lab tests since 2023. This is exactly where longevity demand converts: people do not want a vague age score; they want a private dashboard of what might kill them early.

Neko Health is the strongest preventive-scan signal. In 2025, it raised $260 million, reached a reported $1.8 billion valuation, completed 10,000 scans, and had a 100,000+ person waitlist. The interesting metric is not the scan count. It is that 80% of patients reportedly pre-booked annual scans, which suggests repeat preventive behavior, not just one-time curiosity.

Eli Lilly is arguably the biggest longevity-adjacent winner because GLP-1s turned metabolic risk reduction into a mass pharmaceutical category. In Q1 2026 alone, Lilly generated about $12.9 billion from GLP-1 drugs, with $8.7 billion from Mounjaro and $4.2 billion from Zepbound. That is larger and more concrete than most longevity biotech combined.

Who is losing in longevity right now?

The losers are companies that tried to turn aging biology into drug outcomes before the clinical evidence was strong enough.

Unity Biotechnology is the cleanest warning. Its senolytic osteoarthritis program failed a Phase 2 endpoint in 2020. Its later diabetic macular edema program also disappointed: in 2025, UBX1325 failed to meet the prespecified Phase 2b primary endpoint, and the stock fell around 30% on the news. By mid-2025, Unity was also facing Nasdaq delisting pressure after trading below $1.

BioAge is another hard reset. It raised $170 million privately in early 2024, then completed a $198 million IPO in September 2024. Less than three months later, it halted its Phase 2 azelaprag obesity trial after 11 patients showed elevated liver enzymes. The stock dropped nearly 80%, and the company later abandoned azelaprag.

Calico is the reputational loser. Alphabet launched it as one of the most ambitious aging-biology companies. But in late 2025, AbbVie ended its 11-year partnership with Calico, with reports of 100+ scientists and chemists affected. One partnered ALS drug had already failed to show meaningful efficacy in the HEALEY ALS platform trial.

So, clearly, if a company cannot convert it into a specific disease, endpoint, safety profile, and approvable trial design, the market is no longer willing to pay for the story.

If you want more recent data on this point, please see our latest longevity market report.

Do recent failures weaken the longevity thesis?

Yes, they weaken the fantasy version of longevity. But they do not weaken the practical version.

The failures are concentrated in the hardest part of the market: geroscience drugs. Unity shows how difficult senolytics are to translate. BioAge shows that even a strong aging-data story can collapse on safety. Calico shows that deep capital, elite science, and a Big Pharma partner do not guarantee clinical productivity.

But the practical longevity market is moving in the opposite direction. Oura, Function, Neko, Dexcom’s Stelo, CGMs, GLP-1s, preventive scans, sleep tracking, strength tracking, and metabolic monitoring are growing because they do not need to prove “aging reversal.” They only need to help users identify and manage known risks earlier.

That is the key split. The failures hurt the thesis that we are close to a general anti-aging drug. They strengthen the thesis that near-term longevity will be built around prevention, risk stratification, and better monitoring.

Is longevity, at the end, just better risk management?

Yes. For now, longevity is mostly better orchestration of risks we already know how to measure.

The serious stack is not mysterious: ApoB, HbA1c, blood pressure, visceral fat, VO2 max, grip strength, bone density, sleep, glucose variability, liver function, kidney function, cognition, medication adherence, cancer screening, and cardiovascular risk.

The problem is not that these signals are unknown but that normal healthcare measures them too late, too separately, and with weak follow-up.

That is why the best longevity companies look less like miracle-drug companies and more like coordination layers. Oura owns daily behavior data. Function owns bloodwork frequency. Neko owns preventive scanning. Dexcom is pushing glucose monitoring beyond insulin users. Lilly owns metabolic intervention.

Together, they show where the market is really going: from episodic healthcare to continuous risk management.

Longevity is prevention with an operating system.

If you want more recent data on this point, please see our latest longevity market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.